The present review aims to set GLP-1RAs in the context of Alzheimer’s disease and insulin resistance by presenting the GLP-1’s physiological actions and GLP-1RAs’ neuromodulating mechanisms described so far. Here, GCG is linked to early-onset autosomal dominant Alzheimer disease.